20 articles
Pfizer's landmark trial examines whether tafamidis can safely treat transthyretin amyloid cardiomyopathy, a progressive and often fatal heart condition.
A Phase 2 trial tests once-daily oral resmetirom (MGL-3196) against placebo to reduce LDL-C in patients with inherited high cholesterol.
A comprehensive review reveals tirzepatide improves blood pressure, lipids, liver fat, kidney function, and slashes 10-year cardiovascular risk by up to 23.5%.
A landmark Phase 3 trial evaluates whether omecamtiv mecarbil, a cardiac myosin activator, reduces cardiovascular death in HFrEF patients.
Major study shows tirzepatide reduces cardiovascular and kidney complications by 16% compared to dulaglutide in diabetic patients.
Large clinical trial finds popular diabetes drug semaglutide ineffective at slowing Alzheimer's progression in early-stage patients.
A completed Phase 3 RCT examines whether weekly semaglutide injections improve symptoms and body weight in heart failure patients with obesity.
A pill-form GLP-1 receptor agonist significantly reduced multiple cardiovascular risk markers in both T2D and obesity patients over 26โ36 weeks.
Real-world study of 1,559 octogenarians finds SGLT2 inhibitors reduce all-cause death by 42% and heart failure rehospitalization by 31% with no increase in adverse events.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
New research shows tirzepatide doesn't surpass dulaglutide's cardiovascular benefits despite being a newer diabetes medication.
New analysis reveals oral semaglutide significantly reduces cardiovascular risk factors beyond blood sugar control in type 2 diabetes.
A Phase 1 trial examines if the triple-agonist GLP-1 drug retatrutide changes how the body processes the beta-blocker metoprolol.
Major trial shows semaglutide significantly reduces hospitalizations in obese patients with cardiovascular disease.
A 330-patient multicenter RCT tests whether thymosin ฮฑ1 can curb immune dysregulation and organ dysfunction after acute type A aortic dissection repair.
A major review reveals how SGLT2 inhibitors protect the heart, kidneys, and metabolism through at least seven distinct biological mechanisms.
New research suggests certain diabetes medications may help older adults maintain strength and independence longer.
Small trial explores how amiloride improves oxygen delivery to heart muscle by enhancing potassium transport in red blood cells.
Large analysis reveals women with heart-kidney-metabolic syndrome receive fewer proven therapies than men despite similar cardiovascular risks.
New evidence suggests oral semaglutide sustains long-term improvements in key CVD risk factors, expanding its role beyond diabetes management.
